ClinicalTrials.gg
Active, not recruitingNCT06105151Updated Aug 14, 2026

Study of the Safety, Tolerability, Pharmacokinetics and Food Effects of VV119 Capsules in Chinese Healthy Volunteers

A Phase 1 interventional study of VV119(SAD) and VV119 Placebo(SAD) in Schizophrenia, sponsored by Vigonvita Life Sciences. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-14.

Sponsored by Vigonvita Life Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
82
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 250 studies in Schizophrenia with a site in China — 62 open to participants now, 66 under way, 4 of them phase 3. Schizophrenia · China.

Planned enrollment
127th of 215
82 · median 100
Started
2023
with 16 others
Phase 1
22 of 250
7 open now
Primary completion
2026-10
later than 24 of 65 live
Registered
180th of 250
by date

Among the 250 studies in Schizophrenia with a site in China, this one is the 127th largest by planned enrollment of the 215 interventional ones that give a count, is one of 17 that started in 2023, is one of 22 in phase 1, reaches primary completion later than 24 of the 65 other live ones, and was the 180th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

62 of the 250 studies in Schizophrenia with a site in China are open now. Recruiting first, the newest first:

57 more — sign in →

All 62 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 250 studies in Schizophrenia with a site in China, or all of them as a file.
02

Study summary

This study will consist of 2 parts: Part Ⅰ - Single Ascending Dose (SAD) study, Part Ⅱ - Food Effect (FE) study

Read the detailed description

Part Ⅰ were designed as single-center, randomized, double-blind, placebo-controlled, dose-escalation trials to assess the safety, tolerability, pharmacokinetic (PK) of single oral doses of VV119 in healthy adult subjects.

Part Ⅱ is a single-center, randomized, open label, 2×2 crossover design to assess the high-fat meal effects on PK of a single oral dose of VV119 in healthy adult subjects.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males:aged 18 to 45 years old, males ,Body weight no less than 50.0 kg ; females :Aged 18 to 60 years old ,Body weight no less than 45.0 kg , of 19.0 to 26.0kg/m2,
  2. Medically healthy, Physical examination, vital signs examination, laboratory examination, examination results were normal or abnormal without clinical significance,
  3. Males subjects who are willing to take effective during the study and within 3 months after the study completed; females not of ,
  4. Subjects who are able to understand and follow study plans and instructions; Subjects who have voluntarily decided to participate in this study, and signed the form.

Exclusion criteria

Exclusion Criteria:

Unless otherwise noted, the exclusion criteria were consistent for subjects in the SAD study and FE study. The following subjects will be excluded:

  1. With current or past medical history diseases or dysfunction that affect the clinical trial, evaluated by the investigator, including but not limited to central nervous system, cardiovascular system, respiratory system, digestive system, urinary system, endocrine system, blood system, ophthalmology and other diseases, history of malignant tumor or other diseases that are not suitable for participating in the clinical trial;
  2. With current or previous mental disorders and brain dysfunction, or suicide risk according to the clinical judgment of the investigator, or a history of self-mutilation;
  3. With any surgical condition or condition that may significantly affect the absorption, distribution, metabolism and excretion of the drug, or may pose a hazard to the subjects participating in the trial, such as history of gastrointestinal surgery (gastrectomy, gastrointestinal anastomosis, intestinal resection, etc.), urinary tract obstruction or dysuria, gastroenteritis, gastrointestinal ulcers, history of gastrointestinal bleeding, etc.
  4. With a known history of allergy to investigating drug ingredients or similar drugs, a history of allergic diseases or allergic constitution;
  5. Positive for virus surface antigen (HBsAg), or syphilis antibody (Anti-TP), or antibody (anti-HCV), or antigen/antibody combined detection (HIV-Ag/Ab);
  6. With a history of surgery within 3 months before screening, or have not recovered from surgery, or have an expected surgical plan during the trial;
  7. With a blood donation or blood loss ≥ 400 mL within 3 months before screening, or a blood donation or blood loss ≥ 200 mL within 1 month, or a history of blood product use within 3 months before screening;
  8. Taking any prescription drugs, over-the-counter drugs, and any functional vitamins or herbal products within 2 weeks before screening;
  9. Using any drugs that inhibit or induce hepatic drug metabolizing enzymes , CYP3A5, CYP2D6 (such as inducers - phenobarbital, rifampicin, carbamazepine, phenytoin sodium, , etc.; inhibitors - ketoconazole, itraconazole, cimetidine, clarithromycin, verapamil, erythromycin, etc.) within 4 weeks (or 5 half-lives, whichever is longer) before screening;
  10. Participating in any clinical trial and taking clinical trial drugs within 3 months before screening, or being participating in other clinical trials;
  11. Smoke test positive or smoking more than 5 cigarettes per day or average intake of coffee or tea more than 5 cups per day (200 mL/cup) within 3 months before screening, or unable to stop users during the study;
  12. With alcohol abuse within 1 year before screening, average weekly alcohol intake more than 14 standard units [1 unit = 360 mL beer (alcohol content 5%) or 45 mL spirits (alcohol content 40%) or 150 mL wine (alcohol content 12%)] or positive for alcohol breath test;
  13. With a history of drug abuse within 1 year before screening, or positive for urine drug screening;
  14. With a family history of sudden cardiac death (sudden death age less than 40 years);
  15. With a resting pulse \< 50 beats/min or ≥ 100 beats/min; resting systolic blood pressure \< 85 mmHg or ≥ 140 mmHg; resting diastolic blood pressure \< 50 mmHg or ≥ 90 mmHg; systolic blood pressure decreased by ≥ 20 mmHg and/or diastolic blood pressure decreased by ≥ 10 mmHg and/or accompanied by clinical symptoms within 3 minutes of standing;
  16. Abnormal in 12-lead (ECG), judged by the investigator (e.g., > 450 ms in men and > 470 ms in women);
  17. With the (AST), alanine aminotransferase (ALT), creatinine (Cr), urea (Urea), serum prolactin levels beyond the (ULN);
  18. Having special requirements for food, unable to observe a unified diet or having dysphagia;
  19. Rejecting abide by the following conditions during the trial: smoking, alcohol or caffeine-containing beverages are prohibited, and strenuous exercise is avoided;
  20. Directly related to this clinical trial;
  21. Other subjects that the investigator considers inappropriate for this trial.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    Part Ⅰ - Single Ascending Dose (SAD) study: Experimental

    Subjects will receive VV119 orally for single dose.

    Drug: VV119(SAD)

  • Experimental
    Part Ⅰ - Single Ascending Dose (SAD) study: Placebo

    Subjects will receive VV119 placebo orally for single dose.

    Drug: VV119 Placebo(SAD)

  • Experimental
    Part Ⅱ - Food Effect (FE) study: Experimental

    Subjects will receive VV119 orally for single dose.

    Drug: VV119(FE)

Interventions

  • VV119 0.2 mg Group: 2 subjects will receive VV119 0.2 mg, orally; VV119 0.5 mg Group: 6 subjects will receive VV119 0.5 mg, orally; VV119 1 mg Group: 6 subjects will receive VV119 1 mg, orally; VV119 2 mg Group: 6 subjects will receive VV119 2 mg, orally; VV119 3 mg Group:6 subjects will receive VV119 3 mg, orally; VV119 4.5 mg Group:6 subjects will receive VV119 4.5 mg, orally; VV119 6 mg Group:6 subjects will receive VV119 6 mg, orally; VV119 8 mg Group:6 subjects will receive VV119 8 mg, orally; VV119 10 mg Group:6 subjects will receive VV119 10 mg, orally;

  • DrugVV119 Placebo(SAD)

    VV119 0.5 mg Group: 2 subjects will receive VV119 Placebo 0.5 mg, orally; VV119 1 mg Group: 2 subjects will receive VV119 Placebo 1 mg, orally; VV119 2 mg Group: 2 subjects will receive VV119 Placebo 2 mg, orally; VV119 3 mg Group:2 subjects will receive VV119 Placebo 3 mg, orally; VV119 4.5 mg Group:2 subjects will receive VV119 Placebo 4.5 mg, orally; VV119 6 mg Group:2 subjects will receive VV119 Placebo 6 mg, orally; VV119 8 mg Group:2 subjects will receive VV119 Placebo 8 mg, orally; VV119 10 mg Group:2 subjects will receive VV119 Placebo 10 mg, orally;

  • A:2 mg VV119, following an overnight fast of at least 10 hours for Period 1; 2mg VV119, administered 30 minutes after the start of a high-fat meal for Period 2; B: 2mg VV119, administered 30 minutes after the start of a high-fat meal for Period 1;2mg VV119, following an overnight fast of at least 10 hours for Period 2;

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Incidence of Treatment-Emergent Adverse Events

    Time frame: 23 days after treatment in part Ⅰ;

  2. Incidence of Treatment-Emergent Adverse Events

    Incidence of Treatment-Emergent Adverse Events

    Time frame: 56 days after treatment in part Ⅱ;

  3. Cmax

    maximum observed plasma concentration of VV119 and the main metabolites

    Time frame: 360 hours after dosing in part Ⅰ;

  4. Cmax

    maximum observed plasma concentration of the main metabolites VV119-M2

    Time frame: 480 hours after dosing in part Ⅱ;

  5. area under the plasma concentration time curve from time zero to the last(AUC0-t)

    area under the plasma concentration time curve from time zero to the last of VV119 and the main metabolites

    Time frame: 360 hours after dosing in part Ⅰ;

  6. area under the plasma concentration time curve from time zero to the last(AUC0-t)

    area under the plasma concentration time curve from time zero to the last of the main metabolites VV119-M2

    Time frame: 480 hours after dosing in part Ⅱ;

  7. AUC0-∞

    area under the plasma concentration time curve from time zero to infinity of VV119 and the main metabolites

    Time frame: 360 hours after dosing in part Ⅰ;

  8. AUC0-∞

    area under the plasma concentration time curve from time zero to infinity of the main metabolites VV119-M2

    Time frame: 480 hours after dosing in part Ⅱ;

  9. Tmax

    time at which Cmax occurs of VV119 and the main metabolites of VV119 and the main metabolites

    Time frame: 360 hours after dosing in part Ⅰ;

  10. Tmax

    time at which Cmax occurs of VV119 and the main metabolites of the main metabolites VV119-M2

    Time frame: 480 hours after dosing in part Ⅱ;

  11. t1/2

    half life of elimination of VV119 and the main metabolites

    Time frame: 360 hours after dosing in part Ⅰ;

  12. t1/2

    half life of elimination of the main metabolites VV119-M2

    Time frame: 480 hours after dosing in part Ⅱ;

  13. Apparent Clearance Rate(CL/F)

    apparent clearance of VV119 and the main metabolites

    Time frame: 360 hours after dosing in part Ⅰ;

  14. Apparent Clearance Rate(CL/F)

    apparent clearance of the main metabolites VV119-M2

    Time frame: 480 hours after dosing in part Ⅱ;

  15. Vd/F

    apparent volume of distribution during the terminal phase of VV119 and the main metabolites

    Time frame: 360 hours after dosing in part Ⅰ;

  16. Vd/F

    apparent volume of distribution during the terminal phase of the main metabolites VV119-M2

    Time frame: 480 hours after dosing in part Ⅱ;

  17. Ke

    elimination rate constant of VV119 and the main metabolites

    Time frame: 360 hours after dosing in part Ⅰ;

  18. Ke

    elimination rate constant of the main metabolites VV119-M2

    Time frame: 480 hours after dosing in part Ⅱ;

  19. mean Resident Time from time zero to the last(MRT0-t)

    mean Resident Time from time zero to the last of VV119 of VV119 and the main metabolites

    Time frame: 360 hours after dosing in part Ⅰ;

  20. mean Resident Time from time zero to the last(MRT0-t)

    mean Resident Time from time zero to the last of the main metabolites VV119-M2

    Time frame: 480 hours after dosing in part Ⅱ;

  21. mean Resident Time from time zero to infinity(MRT0-∞)

    mean Resident Time from time zero to infinity of VV119 and the main metabolites

    Time frame: 360 hours after dosing in part Ⅰ;

  22. mean Resident Time from time zero to infinity(MRT0-∞)

    mean Resident Time from time zero to infinity of the main metabolites VV119-M2

    Time frame: 480 hours after dosing in part Ⅱ;

  23. AUC_%Extra

    area under plasma Concentration (AUC) extrapolated of VV119 and the main metabolites

    Time frame: 360 hours after dosing in part Ⅰ;

  24. AUC_%Extra

    area under plasma Concentration (AUC) extrapolated of the main metabolites VV119-M2

    Time frame: 480 hours after dosing in part Ⅱ;

  25. BP

    Blood Plasma Ratio of the main metabolites VV119-M2

    Time frame: 360 hours after dosing in part Ⅰ;

  26. BP

    Blood Plasma Ratio of VV119 and the main metabolites

    Time frame: 480 hours after dosing in part Ⅱ;

Secondary outcomes

  1. Metabolite Identification

    Identification of the structure of the main metabolites of VV119 in plasma,Urine and feces

    Time frame: 360 hours after dosing

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Oct 2026, 36 months after the start.

Of 108 industry-sponsored phase 1 interventional studies under Schizophrenia, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 36 months is above that.

Counting every sponsor, half of 133 studies reached it within 12 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2023
First posted
Oct 27, 2023
StartActual
Oct 27, 2023
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Aug 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06105151
Responsible party
Sponsor
First posted
Oct 27, 2023
Start date
Oct 27, 2023
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Aug 14, 2026

Study contacts

Gang Wang
principal investigator · Beijing Anding Hospital of Capital Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VV119

Start the discussion